Table 1.
Comparison of baseline and transplant characteristics for the voriconazole-cohort and isavuconazole-cohort.
| Characteristic | Total | Voriconazole | Isavuconazole | P-value |
|---|---|---|---|---|
| (n = 305) | (n = 210) | (n = 95) | ||
| Age group, years | 0.182 | |||
| 18—39 | 37 (12.1%) | 30 (14.3%) | 7 (7.4%) | |
| 40—64 | 184 (60.3%) | 126 (60.0%) | 58 (61.1%) | |
| 64+ | 84 (27.5%) | 54 (25.7%) | 30 (31.6%) | |
| Sex | 0.283 | |||
| Female | 113 (37.0%) | 82 (39.0%) | 31 (32.6%) | |
| Male | 192 (63.0%) | 128 (61.0%) | 64 (67.4%) | |
| Race | 0.191 | |||
| White | 253 (83.0%) | 172 (81.9%) | 81 (85.3%) | |
| Black | 21 (6.9%) | 14 (6.7%) | 7 (7.4%) | |
| Asian | 16 (5.2%) | 10 (4.8%) | 6 (6.3%) | |
| Other | 15 (4.9%) | 14 (6.7%) | 1 (1.1%) | |
| Underlying disease | 0.589 | |||
| Leukemia | 151 (49.5%) | 100 (47.6%) | 51 (53.7%) | |
| Lymphoma | 58 (19.0%) | 42 (19.0%) | 16 (16.8%) | |
| MDS | 44 (14.4%) | 29 (13.8%) | 15 (15.8%) | |
| Other1 | 52 (17.0%) | 39 (18.6%) | 13 (13.7%) | |
| Conditioning intensity | 0.0001 | |||
| Ablative | 146 (47.9%) | 93 (44.3%) | 53 (55.8%) | |
| Reduced | 136 (44.6%) | 108 (51.4%) | 28 (29.5%) | |
| Non-ablative | 23 (7.5%) | 9 (4.3%) | 14 (14.7%) | |
| Donor type | 0.002 | |||
| Matched | 195 (67.2%) | 150 (71.4%) | 55 (57.9%) | |
| Mismatched | 78 (25.6%) | 52 (24.8%) | 26 (27.4%) | |
| Haploidentical | 22 (7.2%) | 8 (3.8%) | 14 (14.7%) | |
| Stem cell source | 0.154 | |||
| Marrow | 38 (12.5%) | 21 (10.0%) | 17 (17.9%) | |
| Cord blood | 48 (15.7%) | 34 (16.2%) | 14 (14.7%) | |
| Peripheral blood | 219 (71.8%) | 155 (73.8%) | 64 (67.4%) | |
| GvHD prophylaxis | 0.625 | |||
| TAC or Sirolimus + MMF | 148 (48.5%) | 98 (46.7%) | 50 (52.6%) | |
| Cyclosporin + MMF | 48 (15.7%) | 34 (16.2%) | 14 (14.7%) | |
| CD34+ selection | 109 (35.7%) | 78 (37.1%) | 31 (32.6%) | |
| Recipient CMV serostatus | 0.197 | |||
| Negative2 | 147 (48.2%) | 96 (45.7%) | 51 (53.7%) | |
| Positive | 158 (51.8%) | 114 (54.3%) | 44 (46.3%) | |
| Donor CMV serostatus | 0.261 | |||
| Negative3 | 175 (57.4%) | 116 (55.2%) | 59 (62.1%) | |
| Positive | 130 (42.6%) | 94 (44.8%) | 36 (37.9%) | |
| Acute GvHD grade 4 | 0.396 | |||
| 0—1 | 164 (54.1%) | 116 (55.8%) | 48 (50.5%) | |
| 2—4 | 139 (45.9%) | 92 (44.2%) | 47 (49.5%) |
1
Other included: multiple myeloma (n = 30), myeloproliferative disorder (n = 18), aplastic anemia (n = 3), and non-malignant hematologic disorders (n = 1).
2
Including six patients with equivocal recipient CMV serostatus, four from voriconazole-cohort, and two from isavuconazole-cohort.
3
Including eight patients with equivocal donor CMV serostatus from isavuconazole-cohort.
4
Two patients with unknown acute GvHD grade were excluded from voriconazole group, and in total 303 patients were included for this comparison.
CMV: Cytomegalovirus; GvHD: Graft versus Host Disease; MDS: Myelodysplastic syndrome; MMF: Myophenolate mofetil; TAC: Tacrolimus.